RTP Mobile Logo
Molecular Tumor Board: Biomarker Assessment and Clinical Practice Implications for Patients with Chronic Lymphocytic Leukemia Treated in a Large Regional Oncology Provider
Released May 2018

Proceedings from a roundtable discussion with Drs Dragan Jevremovic, Ann LaCasce and William Wierda on the management of chronic lymphocytic leukemia. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologist-oncologists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

    The clinical course of CLL and outcomes for patients with the disease vary widely, largely based on the presence of individual predictive and other risk factors. This heterogeneity has created a need to identify molecular markers that can be used for prognostication and to guide therapeutic decision-making. Current information on how community-based oncologists approach biomarker testing and how they act on the results is limited. This unique CME activity endeavors to develop a more accurate portrait of how practicing clinicians approach biomarker assessment for patients with CLL. This program features expert perspectives on the practice patterns of select clinicians and presents the state of the art of biomarker analysis and implications for treatment. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of patients with CLL.


    • Recall the incidence, prognostic significance and clinical implications of select biomarkers and chromosomal abnormalities that may be associated with a diagnosis of CLL, and use this information to develop evidence-based testing algorithms in general oncology practice.
    • Evaluate current clinical algorithms used in general oncology practice for patients with newly diagnosed and relapsed/refractory (R/R) CLL, considering the implications of available and emerging clinical trial data.
    • Recall published data and the perspectives of clinical investigators on the management of del(17p) CLL, and use this information to guide first- and later-line treatment decision-making.
    • Appraise the frequency with which biomarker transformation has been observed in patients with R/R CLL, and consider this information as part of therapeutic decision-making for these individuals.
    • Appreciate the recent FDA approval of several novel therapies for newly diagnosed and relapsed/refractory CLL, and discern how these agents can be appropriately integrated into routine clinical practice.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Dragan Jevremovic, MD, PhD
    Assistant Professor of Pathology
    Division of Hematopathology
    Mayo Clinic
    Rochester, Minnesota

    No financial interests or affiliations to disclose.

    Ann S LaCasce, MD, MMSc
    Program Director, Fellowship in Hematology/Oncology
    Associate Professor of Medicine, Harvard Medical School
    Lymphoma Program
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Bristol-Myers Squibb Company, Forty Seven Inc; Consulting Agreement: Seattle Genetics.

    William G Wierda, MD, PhD
    DB Lane Cancer Research Distinguished Professor
    Department of Leukemia
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreement: Sanofi Genzyme; Contracted Research: Genentech, Gilead Sciences Inc, GlaxoSmithKline, Pharmacyclics LLC, an AbbVie Company.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Genentech, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Pharmacyclics LLC, an AbbVie Company.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2018
    Expiration date: May 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Current recommendations for biomarker testing in chronic lymphocytic leukemia (CLL)
(Dr Jevremovic)

Biomarkers and outcomes in CLL
(Dr Wierda)

Changes in biomarkers in CLL over time (Dr LaCasce)

Select Publications